

Curriculum Vitae

LAWRENCE JEFFREY GREEN, MD

Lawrence J Green, MD LLC
9601 Blackwell Road Suite 260
Rockville, MD 20850
(301) 610-0663
Current Affiliation: Private Practice

Born: November 30, 1963
Youngstown, Ohio
Marital status: Married
1997- Present

Faculty Appointment:

George Washington University School of Medicine 1996 - Present
Department of Dermatology
Clinical Professor

Postgraduate Education:

Residency: University of California at Irvine 1992 - 1995
Medical Center
Orange, California
Specialty: Dermatology

Fellowship: University of California at Irvine 1990 - 1992
School of Medicine
Irvine, California
Specialty: Dermatology Research

Internship: Westchester County Medical Center 1989 - 1990
New York Medical College
Valhalla, New York
Specialty: Internal Medicine

Education:

Graduate: New York Medical College 1985 - 1989
Valhalla, New York
Degree: Doctor of Medicine

College: University of Michigan 1981 - 1985
Ann Arbor, Michigan
Degree: Bachelor of Arts in Honors English

Licensure:

- Commonwealth of Virginia Board of Medicine 1997 - Present
Number: 052221
- Maryland Board of Quality Assurance 1997 - Present
Number: D0050346
- District of Columbia Board of Medicine 1997 - Present
Number: 21660

- California State Board of Medical Quality Assurance
Number: G 069239 Current
- United States Drug Enforcement Agency
Number: BG 2471869 Current

Certification:

- American Board of Dermatology 1995, 2005, 2014
- Laser Dermatology Preceptorship
Beckman Laser Institute, Irvine, CA 1993
- National Board of Medical Examiners, Part III 1990
- Basic Life Support “health care provider”
American Heart Association Current
- Advanced Cardiac Life Support
American Heart Association 2000-2008

Awards and Citations:

- Outstanding Clinician of the Year Award
National Psoriasis Foundation 2019
- Advocate of the Year Award
American Academy of Dermatology 2018
- Presidential Citation
American Academy of Dermatology 2017
- Presidential Citation
American Academy of Dermatology 2017
- Patient Safety Hero Award
American Society for Dermatologic Surgery 2015
- Presidential Citation
American Academy of Dermatology 2011
- Senatorial Citation for Advancing Patient Safety
Senate of France 2011
- President’s Council on Volunteerism and Civil Service
President Obama 2010
- President’s Award
American Society for Dermatologic Surgery 2009

Professional Societies:

- American Dermatological Association 2020- Present
- Noah Worcester Dermatology Society 2016 – Present
- Women’s Dermatologic Society 2016- Present
- American Society for Dermatologic Surgery 2000 - Present
- District of Columbia Dermatologic Society 1995 - Present
- National Psoriasis Foundation Professional Member 1994 - Present
- Montgomery County Medical Society/Med Chi 1998 - Present
- American Academy of Dermatology 1992 - Present
- California State Medical Society 1992 - 1995
- New York State Medical Society 1985 - 1990
- American Medical Student Association 1985 – 1989

Professional Activities:

- Board Member
American Academy of Dermatology 2019-
- President
Montgomery County Medical Society 2019-2020
- Board Member
American Society for Dermatologic Surgery 2016-2019
- Online Section Editor, Psoriasis
The Dermatologist 2018-
- Medical Board Member
National Psoriasis Foundation 2016-
- Digital Editorial Board Member
Cutis 2016-
- Member, GAHPP Council
American Academy of Dermatology 2015-2020
- Chair, SkinPAC Board of Advisors
American Academy of Dermatology 2015-2017
- Vice Chair, SkinPAC Board of Advisors 2014-2015

American Academy of Dermatology

- Member, MOHs workgroup
American Academy of Dermatology 2014-2016
- President Elect
Montgomery County Medical Society 2017-2018
- Treasurer, Executive Board Member
Montgomery County Medical Society 2014-2017
- DSMB Safety Officer, National Institute of Health (NIH)
A Randomized Placebo-Controlled Study of the Safety,
Tolerability, Pharmacodynamics, and Clinical Efficacy
of ILV-094 (an anti IL-22 antibody) Administered
Intravenously to Subjects with Atopic Dermatitis 2014-2017
- Editorial Board Member
Journal of Aesthetic and Clinical Dermatology 2013-
- Member, State Policy Committee
American Academy of Dermatology 2013-2019
- Chair, Policy Priorities Committee
American Society for Dermatologic Surgery 2011-2017
- Chair, Scope of Practice Committee
American Society for Dermatologic Surgery 2008- 2010
- Member, SkinPAC board of advisors
American Academy of Dermatology 2008-2017
- Vice President
Montgomery County Medical Society 2017-2018
- Chair, Legislative Committee
Montgomery County Medical Society 2010- 2018
- Committee Member-Coding and Reimbursement Committee
American Academy of Dermatology 2009- 2012
- Committee Member-Scope of Practice
American Society for Dermatologic Surgery 2008- 2010
- Member, Board of Trustees-National Psoriasis Foundation 2005- 2014
- Chair, Research Committee-National Psoriasis Foundation 2005- 2014
- Committee Member - Public Relations Committee
American Society for Dermatologic Surgery 2004-2007
- Committee Member – Task Force on Branding 2003 -2006

American Society for Dermatologic Surgery

- Member, Psoriasis Expert Resource Group 2003 – 2005
American Academy of Dermatology
- Committee Member – Healthcare Finance Committee 2002 – 2007
American Academy of Dermatology
- Medical Advisor for Washington DC area Network 1996 - 1999
National Psoriasis Foundation
- Committee member - Recertification Education Committee 1994 - 1996
American Academy of Dermatology
- Committee member - Task Force on Photobiology 1993 - 1995
American Academy of Dermatology
- Regional representative to Resident Physician's Section 1993 - 1995
American Academy of Dermatology
- California Medical Association resident delegate 1994
and elected for state and national AMA meetings
- Advisor/organizing member for Orange County Network 1992 - 1995
National Psoriasis Foundation

Bibliography:

- Efficacy and Safety of Apremilast in Patients with Mild-to-Moderate Plaque Psoriasis: Results of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Linda Stein-Gold, Kim Papp, David Pariser, Lawrence Green et al
Journal of the American Academy of Dermatology, vol. 86, no. 1, 2022, pp. 77–85
- Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials
Kircik LH, Green L, Guenin E, et al.
J Dermatolog Treat. 2021 Aug 30;1-9
- Tazarotene 0.045% Lotion For Moderate-to-Severe Acne Patients: Pooled Analysis by Age and Sex
Lawrence J Green, James Q DelRosso, Emil A Tanghetti, Eric Guenin
J Drugs Dermatol June 2021 20(6):608-615
- Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: An Analysis of Daxibotulinumtoxin A for Injection in the SAKURA program
Cohen Joel L, Green Lawrence J, Beer Kenneth R et al
Dermatol Surg April 2021 47(4):511-515
- A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dosed Calcipotriene and Betamethasone Dipropionate Cream
Linda Stein Gold, Lawrence J Green, Sunil Dhawan et al
J Drugs Dermatol April 2021 20(4): 420-425

- Improvements in Submental Contour Up to 3 years After ATX-101: Efficacy and Safety Follow-Up of the phase 3 REFINE Trials
Shannon Humphrey, Joel Cohen, Ahish Bhatia, Lawrence J Green, et al
Aesthetic Surgery Journal Feb 22, 2021 <https://doi.org/10.1093/asj/sjab100>
- Wet Wipe Applicators: Exploring the Future of Topical Drug Delivery
Lawrence J Green
Practical Dermatology Feb 2021, 18 (2), 38-40
- DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study Sabrina G. Fabi,* Joel L. Cohen,† Lawrence J. Green et al
Dermatol Surg Jan 2021, 47: (1), 48-54
- Commentary on the Influence of Topical Anesthesia on Superficial Sensitivity: A Double Blind, Randomized, Placebo Controlled Study on 48 Healthy Subjects
Lawrence J Green
Dermatol Surg Dec 2020, 46 (12), 1599
- Advances in Psoriasis Therapy (guest editorial)
Lawrence Green, MD
The Dermatologist August 2020, S9
- Efficacy and Safety of topical Sofpironium Bromide Gel for the Treatment of Primary Axillary Hyperhidrosis: A Phase II, Randomized, Controlled, Double Blind Trial
Brandon Kirsh MD, Stacy Smith MD, Joel Cohen MD, Janet DuBois MD, Lawrence Green MD
J Amer Acad of Dermatol June 2020 82 (6): 1321-27
- Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials
S. Hsu, L.J. Green, M.G. Lebwohl, J.J. Wu, A. Blauvelt and A. Jacobson
British J Dermatol April 2020, 82 (4):880-88
- Long-term Safety and Efficacy of Topical Glycopyrronium Tosylate For the Treatment of Primary Axillary Hyperhidrosis: Post Hoc Pediatric Subgroup Analysis From a 44 Week Open-label Extension study
Adelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al
Pediatr Dermatol March 2020: 00, 1-8
- Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis
Lawrence Green MD, Jeffrey M. Weinberg MD, Alan Menter MD, et al
J Drugs Dermatol Feb 2020: 19 (2): 138-143
- Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study
David M Pariser, Lawrence J Green, Edward L Lain et al
J Clin Aesthet Dermatol. 2019;12(11):E53–E62
- What does efficacy cost? Evidence for Relative Cost-Effectiveness from Biologic Therapies
Jerry Bagel, Ted Lain, Lawrence Green
Practical Dermatology Oct 2019: 62-65

- Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis
Lawrence J Green, Paul Yamauchi, Leon Kircik
J Drugs in Dermatol August 2019 18 (8): 776-786
- Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Linda Stein Gold, Edward Lain, Lawrence J Green, et al
J Drugs Dermatol August 2019 18 (8): 815-820
- A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris.
Tanghetti EA, Kircik LH, Green LJ, et al.
J Drugs Dermatol Jun 2019 1;18(6):542-548
- Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of Efficacy and safety findings by age from two phase 3 randomized controlled trials
Hebert AA, Glaser D, Green L et al
Pediatr Dermatol 2019, 36:89-99
- Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-To-Severe Plaque Psoriasis
Andrew Blauvelt, Lawrence J Green, Mark Lebwohl et al
J Drugs Dermatol March 2019 18: 3, 297-299
- Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials
DeeAnna Glaser, Adelaide Hebert, Alexander Nast, William Werschler, Lawrence Green et al
J Am Acad of Dermatol January 2019 Vol 80:1, 128-138
- Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results of Two Phase III Randomized Controlled Trials.
Lawrence J Green, Francisco Kordel, Fran E Cook-Bolden et al
J Drugs in Dermatology October 2018 Vol 17:10, 1062-1069
- Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results From Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials
Angela Moore, Lawrence J Green, Suzanne Bruce et al
J Drugs in Dermatology September 2018 Vol 17:9, 987-996
- Update on Oral Molecules. Lawrence J Green
The Dermatologist September 2018
- Halobetasol 0.01%/ Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
David Pariser, Lawrence J Green, Linda Stein Gold, et al
J Drugs in Dermatology July 2018 17:7, 723-726
- Safety and Efficacy of Apremilast Through 104 Weeks in Patients With Moderate to Severe

Psoriasis Who Continued on Apremilast or Switched From Etanercept Treatment: Findings From The LIBERATE study
K. Reich, M. Gooderham, A. Bewley, L. Green et al
J European Acad Dermatol Venereol March 2018

- The Maze of Managed Care. Lawrence J Green
The Dermatologist: September 2017; 20-22
- Scalp Seborrheic Dermatitis and Dandruff Treatment Using an Herbal and Zinc Pyrithione Based Shampoo and Scalp Lotion
Deganit Shinar-Barak and Lawrence Green
J of Clinical and Aesthetic Dermatology Jan 2018
- Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab
A pooled analysis of data from 2 phase 3 clinical trials
(AMAGINE-2 and AMAGINE-3)
Andrew Blauvelt, Kim Papp, Mark Lebwohl, Lawrence J Green, et al
J American Acad Dermatol August 2017
- Treatment of Seborrheic Dermatitis Using a Novel Herbal Based Cream
Deganit Shinar-Barak, Rueben del Rio and Lawrence Green
J Aesthetic and Clinical Dermatology April 2017
- Safety and Efficacy of Apremilast Through 104 Weeks in Patients With Moderate to Severe Psoriasis Who Continued on Apremilast or Switched From Etanercept Treatment in the LIBERATE Study
K Reich, M Goodfield, L Green et al.
Poster Presented at Winter AAD meeting Orlando, FL March 2017
- DRM04 for the treatment of axillary hyperhidrosis: Primary results from the ATMOS-1 and ATMOS-2 Phase 3 randomized controlled trials
D Pariser, A Hebert, A Nast, WPWerschler, S Shideler, L Green et al
Poster Presented at Fall Clinical Dermatology Las Vegas, NV and EADV Conference Oct. 2016
- Improvements in Redness and Flaking of Psoriasis Lesions With Brodalumab in the Randomized, Placebo-Controlled, Phase 3 AMAGINE Studies
Paul Yamauchi,¹ Boni Elewski,² Leon Kircik,^{3,4} Lawrence Green et al
Presented at Maui Dermatology Conference February 2017
- Maintenance of clinical efficacy in moderate-to-severe plaque psoriasis: a 52-week Evaluation of brodalumab in three multicenter, double-blind studies of 4363 subjects
K Papp, M Lebwohl, L Green, P Yamauchi et al
Poster Presented at Fall Clinical Dermatology Las Vegas, NV October 2016
- Safety profile of brodalumab in patients with moderate-to-severe plaque psoriasis: a 52-Week Evaluation of Phase III studies
Kim A Papp, Lawrence J Green, Paul S Yamauchi, et al.
Poster Presented at Fall Clinical Dermatology Las Vegas, NV, October 2016
- Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept,

And placebo, in patients with moderate to severe plaque psoriasis: 52-week results from Phase 3b, randomized, placebo-controlled trial (LIBERATE).
J Eur Acad Dermatol Venereol. Accepted manuscript. doi:10.1111/jdv.

- Effect of Apremilast and Etanercept on Pruritus and Health-Related Quality of Life in Patients With Moderate to Severe Plaque Psoriasis: Results from the LIBERATE study
Lawrence Green, Diamond Thaci, Zushoun Zhang, et al
Poster Presented at American Academy of Dermatology Meeting Washington DC March 2016
- Safety of Apremilast and Etanercept Compared With Placebo in Patients With Moderate to Severe Psoriasis: Results From the LIBERATE study
Melinda Gooderham, MD; Jennifer Soung, MD; Lawrence Green, MD; Matthias Augustin
Poster Presented at ODAC meeting Orlando, FL January 2016
- Who Do You Prefer? A Study of Public Preferences for Health Care Provider Type in Performing Cutaneous Surgery and Cosmetic Procedures in the United States
Haider K Bangash, Omar Ibrihimi, Lawrence J Green, et al
Dermatol Surg 2012 38: 10, 1645-1651
- Evaluation of the Efficacy, Tolerability, and Safety of an Over the Counter Acne Regimen Containing Benzoyl Peroxide and Salicylic Acid in Patients with Acne
Leon H Kircik MD, Lawrence J Green MD, Joseph Eastern MD et al
J Drugs in Dermatology 2013; 12 (3): 259-264
- A multicenter double masked placebo-controlled study assessing patient satisfaction with bimotoprost ophthalmic solution 0.03% for increasing eyelash prominence
Joel Cohen MD, Lawrence Green MD, Carrie Caulkins PhD et al
J American Academy of Dermatology 2013; 68 (4)suppl: AB20
- Randomized, Controlled, Evaluator-Blinded Studies Conducted to Compare the Efficacy and Tolerability of 3 Over-the-Counter Acne Regimens in Subjects with Mild or Moderate Acne
Lawrence J Green MD, Leon H Kircik MD, and Jennifer Gwazdauskas MBA
J Drugs in Dermatology 2013; 12 (2): 180-185
- Perceptions of Expertise in Cutaneous Surgery and Cosmetic Procedures: What Primary Care Physicians think
Ibrahimi OA, Bangash H, Green, L et al.
Dermatol Surg 2012 38: 10, 1645-1651
- The Tolerability Profile of Clindamycin 1%/Benzoyl Peroxide 5% Gel vs Adapalene 0.1% Benzoyl Peroxide 2.5% Gel for Facial Acne: Results of Two Randomized Single-Blind, Split face Studies
Lawrence J Green, P Gonzalez
J Clinical and Aesthetic Dermatology 2012 5: 5, 16-24
- Clinical Evidence for the Role of a Topical Anti-inflammatory Agent in Comedonal Acne: Findings from a study of Dapsone 5% gel in combination with Tazarotene 0.1% cream and Adapalene 0.1% gel in patients with acne vulgaris
Emil Tanghetti, MD,^a Sunil Dhawan, MD,^b Lawrence Green, MD et al
J Drugs in Dermatology July 2011

- The Fight for Scope of Practice Regulations for Cosmetic Medical Procedures
Lawrence J Green, MD
The Dermatologist 2012; 18: 11, 57-63
- Clinical evidence for the role of a topical anti-inflammatory agent in Comedonal acne:
Findings From a study of Dapsone 0.5% gel in combination with Tazarotene 0.1% cream in
Patients With Acne vulgaris
Emil Tanghetti, Sunil Dhawan, Lawrence Green, et al
Poster presented at Fall Clinical Dermatology Meeting October 2010
- Randomized Comparison of the safety and efficacy of Tazarotene 0.1% cream and Adapalene
0.1% gel in the treatment of patients with at least moderate acne vulgaris
Emil Tanghetti, Sunil Dwan, Lawrence Green et al
J Drugs in Dermatology 5: 549-558 2010
- A Controlled Randomized Study of Pain Levels in Subjects Treated with Calcium Hydroxylapatite
(Radiesse) Premixed with Lidocaine for Correction of Nasolabial Folds
Ellen Marmur, Lawrence J Green, Mariano Busso
Dermatol Surgery 36: 3, 309-315 2010
- Comparing a Novel Solubilized Benzoyl Peroxide Gel With Benzoyl Peroxide/Clindamycin:
Final Data From a Multicenter, Investigator-Blind, Randomized Study
Leon Kircik MD, Lawrence Green MD, Diane Thiboutot MD et al.
J Drugs in Dermatology Sept 2009
- Comparing a Novel Solubilized Benzoyl Peroxide Gel with Benzoyl Peroxide/Clindamycin:
Final Data From a Multicenter Investigator Blind Randomized Study
Kircik L, Green L, Thibitot D, et al.
Poster Presented at Summer American Academy of Dermatology meeting August 2008
- Acne Challenging Case: Optimizing Therapy in Adolescents
Lawrence J Green
Journal of Clinical and Aesthetic Dermatology 2:4; 20-22 (s), 2009
- Results from a Community-Based Trial of Combination Antimicrobial and Retinoid Therapy
Lawrence J Green and Leon Kircik
Poster presented at World Congress of Dermatology 2008
- Efficacy and tolerability of a Three Step Acne System Containing a Solubilized Benzoyl
Peroxide Lotion Versus a Benzoyl Peroxide Combination Product
Lawrence J Green and James Del Rosso
J of Clinical and Aesthetic Dermatology 1:3; 16-20, 2008
- Moisturizer Use Enhances Facial Tolerability of Tazarotene 0.1% cream without
Compromising Efficacy in Patients with Acne Vulgaris
Tanghetti E, Dralos Z, Dhawan S, Gold M, Kircik L, Green L.
Poster Presented at Hawaii Dermatology Seminar March 2008
- Efficacy and tolerability of a 3-step acne system containing a novel solubilized benzoyl
Peroxide Lotion for normal to dry skin versus a benzoyl peroxide/clindamycin combination
Product: An Investigator-blind, randomized, parallel-group study
Lawrence J Green Poster. Presented at AAD Annual Meeting, San Antonio, TX 2008

- Rationale for Treating Acne with Combination Therapy Based on Clinical Trial Outcomes
Lawrence J Green
Skin & Aging August 2007
- Clinical benefit of using tazarotene+/- clindamycin-benzoyl peroxide adjunctively with minocycline in the treatment of acne vulgaris. Thibitot, D Leyden J Green, L et al.
Poster presented at SDEF Hawaii Dermatology Seminar March 2007, Maui, HI
- Evidence-based results with topical retinoids for acne.
Green L
Skin & Allergy News 2005; September supplement:4-5,14.
- A Clinical Evaluation of Tazarotene 0.1% Gel with and without a High or Mid High Potency Steroid in Patients with Plaque Psoriasis
Lawrence J. Green and Wendy Sadoff
Journal of Cutaneous Medicine and Surgery Mar-Apr;6: 95-102, 2002.
- Are we teaching phototherapy? Results of an informal survey.
Lawrence J. Green
Photodermatology, Photoimmunology, and Photomedicine 15:39-40, 1999.
- The Dermatologist's Guide to Looking Younger.
Lawrence J. Green
Crossing Press, 1999.
- Are we teaching phototherapy? Results of a survey of phototherapy education.
Lawrence J. Green (abs) in *Advancing the science and art of teaching dermatology.*
Ponciano D. Cruz
Archives of Dermatology 134: 858, 1998.
- Neurocutaneous melanosis and Dandy Walker syndrome in an infant.
Lawrence J. Green, Vandana S. Nanda, Gerald M. Roth, Ronald J. Barr.
International Journal of Dermatology 38: 366-373, 1997.
- Pityriasis rotunda in an elderly black American.
Lawrence J. Green, Gary Cole, Edward WB Jeffes, Melissa Watcher.
Journal of Geriatric Dermatology 2: 177-179, 1994.
- A comparison study of 7.5% lactic acid cream and 12% lactic acid lotion in psoriatic patients with xerosis cutis.
Lawrence Green and Gary Cole.
Cosmetic Dermatology 7: 44-45, 1994.
- Photoaging and the Skin: The Effects of Tretinoin.
Lawrence J. Green, Allison McCormick, and Gerald D. Weinstein.
Dermatologic Clinics 11: 97-105, 1993.
- New topical Retinoid gel for therapy of psoriasis: Dose ranging study of AGN 190168.
G.D. Weinstein, L. Green, L.A. Drake, et al.
Journal of Investigative Dermatology (abs) 100: 544, 1993
- Effectiveness of nucleic acid inhibitors on psoriatic plaques.
L. Green, J. McCullough, A. McCormick, E.W. Jeffes, and G. Weinstein.
Journal of Investigative Dermatology (abs) 98: 602, 1992.

- Methotrexate (MTX) therapy of psoriasis: An in vitro model examining the effect of a 24-hour pulse on the growth and proliferation of lymphoid cells and keratinocytes.
E.W. Jeffes, J. McCullough, A. McCormick, J. Dube, M. Dang, L. Green, and G. Weinstein.
Journal of Investigative Dermatology (abs) 98: 592, 1992.
- Immunologic Abnormalities in autoimmune chronic active hepatitis.
Lin RY, Green LJ, and Winny A.
Journal of Rheumatology 16: 1489-93, 1989.
- Immunologic abnormalities in autoimmune chronic active hepatitis.
Lin RY, Green LJ, and Winny A.
Clinical Research (abs) 36: 794A, 1988

FDA Presentations:

- Safety and efficacy of ATX-101 to treat submental fullness
FDA DODAC committee hearing on ATX-101 March 2015
- Safety and efficacy of Radiesse to improve aging hands
Presented on behalf of ASDS to FDA Committee on Plastic Surgical Devices Feb 2015
- Safety and efficacy of secukinamab to treat moderate to severe plaque psoriasis
Presented on behalf of National Psoriasis Foundation to FDA DODAC committee Jan 2015
- Safety and efficacy of Juvéderm Voluma to improve aging cheeks
Presented on behalf of ASDS to FDA Committee on Plastic Surgical Devices March 2014
- The dangers of indoor tanning
Presented on behalf of the AAD at FDA hearing on indoor tanning Oct 2011

Presentations:

- Sunscreen Regulatory Update
Cosmetic Surgery Forum Nashville December 2021
- Botulinum Toxin Trials Update
Cosmetic Surgery Forum Nashville December 2021
- The Skin Microbiome in Atopic Dermatitis
Fall Clinical Conference Las Vegas October 2021
- Botulinum Toxin Clinical Trial Update
Fall Clinical Dermatology Conference Las Vegas October 2021
- New Aesthetic Injectables
Noah Worcester Dermatology Society Meeting Indianapolis June 2021
- Implications of the 2020 Election for Dermatologists
Fall Clinical Dermatology Conference November 2020

- New treatments for buttocks cellulite
Israel Society for Dermatologic Surgery Annual Meeting Tel Aviv, Israel Dec 2019
- Update on Clinical Therapeutics
Noah Worcester Dermatology Meeting Palm Springs, CA April 2019
- American Society for Dermatologic Surgery Association Update
Kansas Society for Dermatology Meeting Lawrence, KS August 2018
- Oral Therapies for Psoriasis
American Academy of Dermatology Summer Meeting Chicago, IL July 2018
- American Academy of Dermatology Association Update
Noah Worcester Dermatology Society Annual Meeting, Savannah, GA March 2018
- Topical Acne Therapies
American Academy of Dermatology Annual Meeting, San Diego, CA Feb 2018
- Rosacea Update
American Academy of Dermatology Annual Meeting San Diego, CA Feb 2018
- Acne Expert Tips
Winter Clinical Dermatology Meeting Maui, HI Jan 2018
- Update in botulinum Toxin Therapy
Israel Society for Dermatologic Surgery Annual Meeting Dec 2017
- New Treatments for Hyperhidrosis
Israel Society for Dermatologic Surgery Annual Meeting Dec 2017
- Acne Therapy Update
New York Society for Dermatologic Surgery Meeting Nov 2017
- Expert Medical and Surgical Tips
Fall Clinical Dermatology Meeting Oct 2017
- Acne and Rosacea Therapeutic Update
Florida Society for Dermatology Meeting June 2017
- What is Affecting Dermatologist Payments?
Winter Clinical Dermatology Conference Jan 2017
- ATX-101(Kybella) for the reduction of submental fat: Clinical trial results
Israeli Society for Dermatologic Surgery Annual Meeting, December 2014
- Congressional Capitol Hill Briefing on Psoriasis
Presented on behalf of the National Psoriasis Foundation September 2014
- A multicenter double masked placebo-controlled study assessing patient satisfaction with bimatoprost ophthalmic solution 0.03% for increasing eyelash prominence. Lawrence J Green
Poster (P6806)

Presented at 2013 American Academy of Dermatology Annual Meeting

- Update on Consumer Acne Market. Lawrence J Green
Presented at Orlando Dermatology and Aesthetic Conference January 2011
- How to Build a Cosmeceutical Dispensing Practice. Lawrence J Green
Presented at Orlando Dermatology and Aesthetic Conference January 2011
- Optimizing Acne Therapy. Lawrence J Green
Presented at Fall Clinical Dermatology Conference Las Vegas, NV Oct 19, 2008
- Cosmeceutical Update and Acne Update. Lawrence J Green
Presented at Coastal Dermatology Meeting Carmel, CA Oct 2008
- Update on phototherapy. Lawrence J Green
Presented at AAD meeting in the Psoriasis Symposium, July 2005
- Noninvasive Management of the Aging Face. Lawrence J Green
Presented at Carolina Dermatology Winter Meeting, January 2004
- New Biologic Therapies for Psoriasis. Lawrence J Green
Presented at Georgetown University Grand Rounds, George Washington University, and dinner meetings in Baltimore and Washington DC, September 2003-February 2004
- Safety of Tacrolimus 0.03 ointment in the pediatric and adult population in the treatment of atopic dermatitis . Lawrence J Green
Presented at Hawaii Dermatology Seminar, February 2003
- Rationale for allowing reimbursement for XTRAC laser therapy for psoriasis and other inflammatory skin disease. Lawrence J. Green
Presented before the RUC committee of CMS, April 2002
- A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Tolerability of Treating Facial Acne Vulgaris Once Daily With Tazarotene 0.1% Gel or Adapalene 0.1% Gel
A Shalita, G Webster, N Lowe, B Miller, B Solomon, L Guenther, K Loven, L Green, Y Poulin
Presented at American Academy of Dermatology Meeting, Washington DC, March 2001
- Is there a cure for wrinkles? Lawrence J. Green.
Presented at Shady Grove Hospital, October 5, 1998
- The differential diagnosis of hair loss. Lawrence J. Green
Presented at Fairfax Hospital Department of Medicine Grand Rounds, June 25, 1998
- Psoriasis: Topical therapeutic alternatives. Lawrence J. Green
Presented at Tidewater Dermatologic Society meeting January 24, 1999, Columbus Dermatologic Society meeting December 6, 1998, and Orlando Dermatologic Society meeting June 3, 1998
- Is there a cure for wrinkles? Lawrence J. Green
Presented at Fairfax Hospital, May 19, 1998
- Are we teaching photomedicine? Lawrence J. Green
Presented at Professors of Dermatology Meeting, Orlando, March 1, 1998

- Are we teaching photomedicine? Lawrence J. Green.
Presented at annual Photomedicine Society Meeting, Orlando, February 26, 1998
- Psoriasis: Topical therapeutic alternatives. Lawrence J. Green.
Presented at Jacksonville Dermatology Society Meeting, October 26, 1997
- Psoriasis. Lawrence J. Green.
Presented at Univ. of Virginia, Department of Dermatology Grand Rounds, September 4, 1997
- Psoriasis: Topical therapeutic alternatives. Lawrence J. Green.
Presented at dermatologist meetings in Baltimore, Raleigh, Albany, Rochester, Kansas City, Tampa, Jacksonville, Wilmington, Knoxville, Cincinnati, Dayton, St. Louis, Minneapolis, Tulsa, Omaha, and Philadelphia from August 1997-Present
- Psoriasis. Lawrence J. Green
Presented at George Washington University and Washington Hospital Center Department of Dermatology Resident teaching conference, February 5, 1997
- Rejuvenate Your Skin Seminar. Lawrence J. Green and Larry McNelly.
Presented at Alexandria Hospital, February 1997
- Psoriasis. Lawrence J. Green
Presented at Department of Medicine Grand Rounds (Fairfax Hospital and Arlington Hospitals) February 1996
- Pityriasis Rotunda in a Black American with W. African ancestors. Lawrence J. Green.
Presented at Advanced Seminars in Dermatology meeting August 1993
- New topical Retinoid gel for therapy of psoriasis: Dose ranging study of AGN 190168. G.D. Weinstein, L. Green, L.A. Drake, et al.
Presented at Society of Investigative Dermatology meeting April 1993
- Effectiveness of intralesional nucleic acid inhibitors on psoriatic plaques. L. Green, J. McCullough, A. McCormick, E.W. Jeffes, A. Korey, E. Orenberg, and G. Weinstein.
Presented at Society of Investigative Dermatology meeting, April 1992
- Methotrexate (MTX) therapy of psoriasis: An *in vitro* model examining the effect of a 24-hour MTX pulse on the growth and proliferation of lymphoid cells and keratinocytes. E.W. Jeffes, J. Presented at Society of Investigative Dermatology meeting April 1992
- Porphyrin affinity towards serum lipoproteins in patients with protoporphyria and porphyria cutanea tarda. Lawrence Green and Maureen Poh-Fitzpatrick.
Presented at New York Medical College Student Research Forum June 1989
- Immunologic abnormalities in autoimmune chronic active hepatitis. Lin RY, Winny A, and Green LJ.
Presented at American Federation of Clinical Research Conference-Eastern Section October 1988

Investigational Research:

- A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis (ARRECTOR)
August 2021-present
- A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis
August 2021-present
- A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis
May 2021-present
- A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
April 2021-present
- A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis
April 2021-present
- An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating. (+ An Evaluation of Skin pH for a Subset of Subjects Treated in the Sahara Study)
March 2021-present
- A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects with Axillary Hyperhidrosis (the “Cardigan I Study”)
November 2020-October 2021
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial To Evaluate The Efficacy And Safety of FB-401 In Children, Adolescent And Adult Subjects (Ages 2 Years And Older) With Mild to Moderate Atopic Dermatitis
October 2020-November 2021
- A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
Sep 2020-November 2021
- A Multi-Center, Randomized, Double- Blind, Placebo Controlled Study To Compare Efficacy and Safety of Trifarotene (CD5789) Cream When Used with an Oral Antibiotic for the Treatment of Severe Acne Vulgaris
Aug 2020- present
- A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects with Chronic Hand Eczema
Jul 2020-October 2021

- A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects with Seborrheic Dermatitis
May 2020-present
- A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis
March 2020-July 2021
- A Phase 3, Multicenter, Open-Label, Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302
March 2020-October 2021
- A Phase 3, 8 Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis
December 2019-February 2021
- A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults.
February 2020-July 2021
- A Phase 2 Efficacy and Safety Study of Tapinarof for the treatment of Plaque Psoriasis in Adults.
October 2019-Sep 2020
- A Multi-Center, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis
August 2019-present
- A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Mild-to-Moderate Plaque Psoriasis.
May 2019-Oct 2020
- A Phase 3 Open Label Safety Study of A-101 Topical Solution for The Treatment of Common Warts.
March 2019-Feb 2020
- A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-Severe Plaque Psoriasis.
January 2019-Feb 2020
- A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris
January 2019-Dec 2019
- A Multi-Center, Randomized, Open-Label, Phase 3 Long-Term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects with Axillary Hyperhidrosis
October 2018-March 2020
- A phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Of A-101 Topical Solution Applied Twice A Week in Subjects with Common Warts
September 2018- Jan 2020

- A Multicenter, Randomized, Double-Blind, Placebo-Controlled study comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in patients with Moderate-to-Severe plaque psoriasis
Jun 2018-May 2020
- A randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects with Pruritus Associated with Psoriasis Vulgaris
Mar 2018-Mar 2019
- A randomized, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream compared to MC2-01 Cream Vehicle and Active Comparator in subjects with mild-to-moderate Psoriasis Vulgaris.
Aug2017-April 2018
- An Open Label Multicenter Trial To Assess the Safety of Single Repeat Treatment of Daxibotulinum Toxin A For Injection For Treatment of Moderate to Severe Glabellar Lines
Dec 2016-2018
- A Multicenter Evaluation of the Safety and Efficacy of Sarecycline Tablets in the Treatment of Acne Vulgaris
January 2015-2017
- A Randomized Double-Blind Placebo Controlled Parallel Group Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab (300 mg) as Assessed by the Psoriasis Scalp Severity Index at 12 Weeks of Treatment Compared to Placebo
March 2015-2017
- A Multicenter Randomized Double Blinded Placebo Controlled Study Evaluating the Safety And Efficacy of LIPO-22 for the Reduction of Central Abdominal Bulging Due to Abdominal Fat In Non-Obese Subjects
May 2015-2016
- A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
April 2014-2015__
- Efficacy and Safety of Ingenol mebutate gel 0.06% when applied once daily for 2,3, or 4 Consecutive Days to a treatment area of approximately 250 cm² on trunk and extremities In Subjects with Actinic Keratosis
April 2014-August 2014
- A safety and efficacy study to compare Dapsone Dermal Gel with Vehicle Control in Patients With Acne Vulgaris
January 2014- January 2015
- A Randomized double-blind vehicle controlled parallel group study of the safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene Lotion 0.05% and the efficacy Of Betamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis
December 2013-December 2015

- Phase 3b, multicenter, randomized, placebo controlled double blind, double-dummy, study Of the efficacy and safety of Apremilast (CC-10004), Etanercept, and Placebo in subjects with moderate to severe plaque psoriasis
January 2013-2014
- A Phase 3 Study to evaluate the efficacy and safety of induction and maintenance regimens of Brodalumab compared with placebo and ustekinumab in subjects with moderate to severe Plaque Psoriasis: AMAGINE-2
December 2012-2016
- A Double Blind, Randomized, Parallel-Group, Vehicle Controlled Multicenter Study Comparing Adapalene 0.1% and Benzoyl Peroxide 2.5% Generic to Reference Listed Drug In the Treatment Of Acne Vulgaris
October 2012- March 2013
- Multicenter randomized double-blind placebo-controlled Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area
February 2012-December 2012
- A Phase 3 randomized, Double-blind, 12 Week Vehicle Controlled Parallel Group Study Assessing the Efficacy and Safety of CD5024 1% Cream versus Vehicle Cream in Subjects with Papulo-Pustular Rosacea
February 2012-December 2012
- A Multicenter, Double-Masked, Placebo Controlled Study Assessing Patient Satisfaction with LATISSE for Increasing Eyelash Prominence
November 2011- February 2012
- An Open Label, 12 Week Study to Evaluate the Safety and Efficacy of the MaxClarity System in Subjects with Acne
June-October 2011
- A Non-Inferiority Study Comparing Aczone Gel 5% and Differin 0.3% Gel Dual therapy to Dual Therapy with Duac Topical Gel and Differin 0.3% Gel for the Treatment of Facial Acne Vulgaris
Oct 2010-February 2011
- A national, multi-center, prospective, randomized, double blind, 4 arm, parallel group, 8 Week study in subjects with psoriasis vulgaris on the non-scalp regions of the body
November 2010-February 2011
- Comparative Efficacy and Safety of Tazacort 0.1% facial cream and Differin 0.3% gel in the Treatment of moderate to severe facial acne vulgaris
Jan-July 2009
- A single-blind randomized comparative split-face study evaluating the tolerability of Duac Topical Gel to Epiduo in the treatment of acne vulgaris
Sept 2009-Dec 2009
- A randomized, single-blind controlled split face study to evaluate and compare the efficacy and safety of Maxclarity and Proactive in subjects with acne
Sept 2009-Dec 2009

- An Evaluation of Pain with the use of Lidocaine-Mixed Radiesse for the Treatment of Nasolabial Folds
October-November 2008
- A Multi-Center, Investigator Blinded Randomized Study to Evaluate the Tolerability and Efficacy of Clenziderm MD vs. Benzaclin Topical Gel in the Treatment of Moderate Facial Acne Vulgaris
May-September 2008
- Comparative Efficacy and Safety of Tazorac 0.1% cream and Differin 0.3% gel in the Treatment of Moderate to Severe Acne Vulgaris
November 2007-April 2008
- An Investigator blinded, randomized study to evaluate the tolerability and efficacy of CLENZIderm MD (normal to dry skin) vs Duac topical gel in the treatment of mild to moderate facial acne vulgaris
March-June 2007
- Comparative tolerability and efficacy of tazorac 0.1% cream and Retin-A Micro 0.04% in the Treatment of mild to moderate facial acne vulgaris
December-June 2007
- Combined effects of Duac topical gel with Retin-A 0.025 gel compared to triple therapy with 1% clindamycin gel, Retin-A 0.025 gel and 5% benzoyl peroxide wash in the treatment of acne vulgaris
November 2006-March 2007
- Community based evaluation of combination therapy using Duac Topical Gel and a topical retinoid in the treatment of moderate to severe acne vulgaris
September 2006-December 2006
- Observational safety surveillance study utilizing Enbrel to treat psoriasis: A 5-year commitment
May 2006-June 2011
- A comparison of the tolerability and efficacy of tazorac 0.1% cream used in combination with minocycline versus the combination of tazorac 0.1% cream and duac topical gel versus minocycline alone for the treatment of moderate to severe acne vulgaris
Sept. 2005-Jan. 2006
- A pilot study comparison initiating treatment with either Duac Topical gel, Differin 0.1% gel, or both for 4 weeks followed by either combination therapy or Differin 0.1% gel alone for the treatment of acne vulgaris for 8 additional weeks Duac gel with and without adapalene 0.1% gel in the treatment of facial acne vulgaris
Sept. 2005-Jan 2006
- An evaluation of the efficacy of tacrolimus 0.03% ointment versus placebo in adults with mild-moderate atopic dermatitis.
December 2001-April 2002
- An evaluation of the safety and efficacy of Tazorac 0.1% gel and Differin 0.1% gel in the treatment of subjects with facial acne vulgaris.
July 1999-January 2000

- Tazorac 0.1% observation study in stable plaque psoriasis. October 1997-April 1998.
- A double-blind evaluation of topical methotrexate in combination with dipyrimadole in subjects with plaque psoriasis. July-October 1993
- A double blind, bilateral comparison study of two topical retinoic acid (tretinoin) cream formulations and a vehicle control on patients with psoriasis. March-June 1992
- A randomized, double blind vehicle-controlled study of topical clobetasol gel 0.05% in the treatment of moderate to severe plaque psoriasis. April-June 1992
- Double blind bilateral paired comparison study of Penecare 7.5% cream vs. 12% Lac-Hydrin lotion in the treatment of xerosis cutis in patients with psoriasis. March-June 1992
- Low dose intravenous photofrin photodynamic therapy of psoriasis. February 1991-June 1992
- The role of serum growth factors in skin disease. November 1990-June 1992
- Comparison of AGN 190168 0.1% and 0.5% gels applied once daily and twice daily in the treatment of psoriasis. November 1991-March 1992
- Intralesional methotrexate therapeutic implants for the treatment of psoriasis. July 1991-April 1992
- A double blind, randomized, placebo-controlled study of the safety and efficacy of topical Premarin cream to improve the appearance of aging facial skin. July 1991-March 1992
- An open label safety evaluation of adjunctive topical products used by subjects applying Renova in the treatment of photodamage. August 1991-February 1992
- Evaluation of the safety and efficacy of tretinoin emollient cream (TEC-II) 0.05% in the treatment of photodamaged facial skin. July 1990-April 1991
- Double blind vehicle-controlled comparison evaluation of methotrexate in patients with plaque psoriasis. October 1990-April 1991
- Porphyrin affinity towards serum lipoproteins in patients with protoporphyria and porphyria cutanea tarda. January-April 1989